SCHEMBL6286258

SCHEMBL6286258

COc1ccc(-c2cc3c([nH]2)CCCC3)cc1NCc1cccc(O)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.46
ALDH1A1 P00352 8/20 0.46
KDM4E B2RXH2 7/20 0.46
HPGD P15428 5/20 0.46
KMT2A Q03164 4/20 0.46
LMNA P02545 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
MEN1 O00255 2/20 0.40
HDAC8 Q9BY41 3/20 0.39
HTR6 P50406 1/20 0.38
GAA P10253 5/20 0.38
POLB P06746 2/20 0.38
ALOX15 P16050 2/20 0.38
HSD17B10 Q99714 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
CALM1 P0DP23 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
PI4KB Q9UBF8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6286957 0.83 SMN1; SMN2 (0.51) MAPTALDH1A1KDM4EHPGDKMT2A
SCHEMBL6282813 0.77 CCNB2 (0.56) MAPTALDH1A1KDM4EHPGDKMT2A
SCHEMBL6279135 0.77 KMT2A (0.44) MAPTALDH1A1KDM4EHPGDKMT2A
SCHEMBL6287117 0.77 RIPK1 (0.59) MAPTALDH1A1KDM4EHPGDKMT2A
SCHEMBL6496194 0.77 MAPT (0.43) MAPTALDH1A1KDM4EHPGDKMT2A
SCHEMBL6287129 0.76 RIPK1 (0.43) MAPTALDH1A1KDM4EHPGDKMT2A
SCHEMBL6285617 0.76 KMT2A (0.43) MAPTALDH1A1KDM4EHPGDKMT2A
SCHEMBL6286663 0.75 RIPK1 (0.42) MAPTALDH1A1KDM4EHPGDKMT2A
SCHEMBL6282949 0.75 F3 (0.45) MAPTALDH1A1KDM4EHPGDKMT2A
SCHEMBL6282806 0.75 F3 (0.53) MAPTALDH1A1KDM4EHPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040014759-A1 6,5-Fused bicyclic heterocycles PICARD JOSEPH ARMAND (US) 2004-01-22 US claimed
EP-1294718-A2 6,5-FUSED BICYCLIC HETEROCYCLES WARNER-LAMBERT COMPANY LLC (US) 2003-03-26 EP claimed
WO-2001096336-A2 6,5-FUSED BICYCLIC HETEROCYCLES WARNER-LAMBERT COMPANY (US) 2001-12-20 WO claimed
US-6943174-B2 6,5-Fused bicyclic heterocycles WARNER-LAMBERT COMPANY (US) 2005-09-13 US disclosed
US-20040014759-A1 6,5-Fused bicyclic heterocycles PICARD JOSEPH ARMAND (US) 2004-01-22 US disclosed
EP-1294718-A2 6,5-FUSED BICYCLIC HETEROCYCLES WARNER-LAMBERT COMPANY LLC (US) 2003-03-26 EP disclosed
WO-2001096336-A2 6,5-FUSED BICYCLIC HETEROCYCLES WARNER-LAMBERT COMPANY (US) 2001-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014759-A1 6,5-Fused bicyclic heterocycles ALOX15, ALOX5, ALOX15B MAPT 4625/4885ALDH1A1 522/4885KDM4E 2221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.